Sumitomo, Otsuka Both Stand To Gain From CNS Partnership

Sumitomo Dainippon Pharma Co., Ltd.’s Sunovion Pharmaceuticals subsidiary and Otsuka Holdings Co., Ltd. both stand to gain from a development and commercialization deal around four central nervous system (CNS) drugs that brings together two major players in psychiatric drugs while also providing two compounds already in late-stage development. In particular, Sumitomo will benefit from Otsuka’s CNS expertise and marketing heft.

Sumitomo and Sunovion, along with Otsuka, announced a deal on 30 September worth up to $890m – including a $270m upfront payment and milestones up to $620m – for the four assets